Citadel Advisors
TRAW icon

Citadel Advisors’s Traws Pharma TRAW Stock Holding History

Citadel Advisors’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,819
Closed -$28K – 14461
2025
Q4 		$28K Buy
+24,819
New +$55.2K ﹤0.01% 12246
2024
Q3 		– Sell
-4,840
Closed -$54.1K – 15433
2024
Q2 		$54.1K Buy
4,840
+3,367
+229% +$54.3K ﹤0.01% 11670
2024
Q1 		$37.2K Buy
+1,473
New +$28.4K ﹤0.01% 12472
2023
Q1 		– Sell
-748
Closed -$12K – 15651
2022
Q4 		$12K Sell
748
-962
-56% -$18.1K ﹤0.01% 13532
2022
Q3 		$38K Sell
1,710
-670
-28% -$20.3K ﹤0.01% 11786
2022
Q2 		$79K Buy
+2,380
New +$80.3K ﹤0.01% 11604
2022
Q1 		– Sell
-1,625
Closed -$104K – 14749
2021
Q4 		$104K Sell
1,625
-1,199
-42% -$96.4K ﹤0.01% 12685
2021
Q3 		$270K Buy
+2,824
New +$364K ﹤0.01% 11301
2021
Q2 		– Sell
-155
Closed -$58K – 14566
2021
Q1 		$58K Sell
155
-1,362
-90% -$514K ﹤0.01% 12828
2020
Q4 		$265K Buy
1,517
+749
+98% +$86.9K ﹤0.01% 9278
2020
Q3 		$81K Buy
+768
New +$190K ﹤0.01% 9387
2020
Q2 		– Sell
-483
Closed -$55K – 10629
2020
Q1 		$55K Buy
483
+328
+212% +$51.5K ﹤0.01% 8990
2019
Q4 		$22K Buy
+155
New +$29K ﹤0.01% 8928
2019
Q3 		– Sell
-45
Closed -$48K – 9849
2019
Q2 		$48K Buy
+45
New +$62K ﹤0.01% 8741
2019
Q1 		– Sell
-37
Closed -$29K – 9967
2018
Q4 		$29K Buy
+37
New +$63.1K ﹤0.01% 8631
2018
Q3 		– Sell
-9
Closed -$20K – 9779
2018
Q2 		$20K Buy
+9
New +$26.1K ﹤0.01% 8652
2018
Q1 		– Sell
-2
Closed -$17K – 8876
2017
Q4 		$17K Buy
+2
New +$20.6K ﹤0.01% 7851
2017
Q1 		– Sell
-3
Closed -$41K – 8144
2016
Q4 		$41K Buy
+3
New +$44.5K ﹤0.01% 6913
2016
Q2 		– Sell
-1
Closed -$19K – 7505
2016
Q1 		$19K Hold
1
– – ﹤0.01% 6482
2015
Q4 		$46K Buy
+1
New +$74.1K ﹤0.01% 7385
2014
Q1 		– Hold
0
– -$161K – 8041
2013
Q4 		– Hold
0
– – – 5228

Other funds holding TRAW

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's TRAW Position: Q1 2026 in Review

Citadel Advisors sold out of Traws Pharma (TRAW) in Q1 2026, closing a stake of 24,819 shares — an estimated $28K sold.

Citadel Advisors first reported a position in TRAW in Q4 2015 and held it in 20 quarters. The position peaked at $270K in Q3 2021. 28 funds tracked by Wall St. Rank hold TRAW as of Q1 2026.

  • Citadel Advisors reported no remaining Traws Pharma position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 24,819 Traws Pharma shares in Q1 2026, an estimated $28K.
  • Citadel Advisors first reported a position in Traws Pharma in Q4 2015 and held it in 20 quarters.
  • Citadel Advisors's Traws Pharma position peaked at $270K in Q3 2021.
  • 28 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.